Accès gratuit
Numéro
Med Sci (Paris)
Volume 24, Numéro 2, Février 2008
Page(s) 177 - 184
Section M/S revues
DOI https://doi.org/10.1051/medsci/2008242177
Publié en ligne 15 février 2008
  1. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors : subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41 : 661–90.
  2. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors : multiple roles in inflammation and immune modulation. Pharmacol Ther 2004; 103 : 147–66.
  3. Urade Y, Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 2000; 1482 : 259–71.
  4. Herlong JL, Scott TR. Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett 2006; 102 : 121–31.
  5. Kanaoka Y, Fujimori K, Kikuno R, et al. Structure and chromosomal localization of human and mouse genes for hematopoietic prostaglandin D synthase. Conservation of the ancestral genomic structure of sigma-class glutathione S-transferase. Eur J Biochem 2000; 267 : 3315–22.
  6. Tanaka K, Ogawa K, Sugamura K, et al. Cutting edge : differential production of prostaglandin D2 by human helper T cell subsets. J Immunol 2000; 164 : 2277–80.
  7. Urade Y, Hayaishi O. Prostaglandin D synthase : structure and function. Vitam Horm 2000; 58 : 89–120.
  8. Ueno N, Takegoshi Y, Kamei D, et al. Coupling between cyclooxygenases and terminal prostanoid synthases. Biochem Biophys Res Commun 2005; 338 : 70–6.
  9. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002; 68-69 : 165–75.
  10. Loftin CD, Tiano HF, Langenbach R. Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002; 68-69 : 177–85.
  11. Fujimori K, Kadoyama K, Urade Y. Protein kinase C activates human lipocalin-type prostaglandin D synthase gene expression through de-repression of notch-HES signaling and enhancement of AP-2 beta function in brain-derived TE671 cells. J Biol Chem 2005; 280 : 18452–61.
  12. Mong JA, Devidze N, Frail DE, et al. Estradiol differentially regulates lipocalin-type prostaglandin D synthase transcript levels in the rodent brain : evidence from high-density oligonucleotide arrays and in situ hybridization. Proc Natl Acad Sci USA 2003; 100 : 318–23.
  13. Li L, Yang Y, Stevens RL. RasGRP4 regulates the expression of prostaglandin D2 in human and rat mast cell lines. J Biol Chem 2003; 278 : 4725–9.
  14. Samy ET, Li JC, Grima J, et al. Sertoli cell prostaglandin D2 synthetase is a multifunctional molecule : its expression and regulation. Endocrinology 2000; 141 : 710–21.
  15. Boie Y, Sawyer N, Slipetz DM, et al. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 1995; 270 : 18910–6.
  16. Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001; 193 : 255–61.
  17. Kobayashi T, Narumiya S. Function of prostanoid receptors : studies on knockout mice. Prostaglandins Other Lipid Mediat 2002; 68-69 : 557–73.
  18. Pinzar E, Kanaoka Y, Inui T, et al. Prostaglandin D synthase gene is involved in the regulation of non-rapid eye movement sleep. Proc Natl Acad Sci USA 2000; 97 : 4903–7.
  19. Huang ZL, Urade Y, Hayaishi O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr Opin Pharmacol 2007; 7 : 33–8.
  20. Rolin S, Masereel B, Dogne JM. Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol 2006; 533 : 89–100.
  21. Matsuoka T, Hirata M, Tanaka H, et al. Prostaglandin D2 as a mediator of allergic asthma. Science 2000; 287 : 2013–7.
  22. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007; 6 : 313–25.
  23. Kostenis E, Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 2006; 12 : 148–58.
  24. Schuligoi R, Grill M, Heinemann A, et al. Sequential induction of prostaglandin E and D synthases in inflammation. Biochem Biophys Res Commun 2005; 335 : 684–9.
  25. Kobayashi T, Narumiya S. Prostanoids in health and disease ; lessons from receptor-knockout mice. Adv Exp Med Biol 2002; 507 : 593–7.
  26. Hasumoto K, Sugimoto Y, Yamasaki A, et al. Association of expression of mRNA encoding the PGF2 alpha receptor with luteal cell apoptosis in ovaries of pseudopregnant mice. J Reprod Fertil 1997; 109 : 45–51.
  27. Lumsden MA, Kelly RW, Templeton AA, et al. Changes in the concentration of prostaglandins in preovulatory human follicles after administration of hCG. J Reprod Fertil 1986; 77 : 119–24.
  28. Schell C, Frungieri MB, Albrecht M, et al. A Prostaglandin D2 system in the human testis. Fertil Steril 2007; 88 : 233–6.
  29. Cheuk BL, Chew SB, Fiscus RR, Wong PY. Cyclooxygenase-2 regulates apoptosis in rat epididymis through prostaglandin D2. Biol Reprod 2002; 66 : 374–80.
  30. Saito S, Tsuda H, Michimata T. Prostaglandin D2 and reproduction. Am J Reprod Immunol 2002; 47 : 295–302.
  31. Wilhelm D, Martinson F, Bradford S, et al. Sertoli cell differentiation is induced both cell-autonomously and through prostaglandin signaling during mammalian sex determination. Dev Biol 2005; 287 : 111–24.
  32. Wilhelm D, Hiramatsu R, Mizusaki H, et al. SOX9 regulates prostaglandin D synthase gene transcription in vivo to ensure testis development. J Biol Chem 2007; 282 : 10553–60.
  33. Malki S, Nef S, Notarnicola C, et al. Prostaglandin D2 induces nuclear import of the sex-determining factor SOX9 via its cAMP-PKA phosphorylation. EMBO J 2005; 24 : 1798–809.
  34. Nef S, Schaad O, Stallings NR, et al. Gene expression during sex determination reveals a robust female genetic program at the onset of ovarian development. Dev Biol 2005; 287 : 361–77.
  35. Vidal VP, Chaboissier MC, de Rooij DG, Schedl A. Sox9 induces testis development in XX transgenic mice. Nat Genet 2001; 28 : 216–7.
  36. Barrionuevo F, Bagheri-Fam S, Klattig J, et al. Homozygous inactivation of Sox9 causes complete XY sex reversal in mice. Biol Reprod 2006; 74 : 195–201.
  37. Morais da Silva S, Hacker A, Harley V, et al. Sox9 expression during gonadal development implies a conserved role for the gene in testis differentiation in mammals and birds. Nat Genet 1996; 14 : 62–8.
  38. Gasca S, Canizares J, De Santa Barbara P, et al. A nuclear export signal within the high mobility group domain regulates the nucleocytoplasmic translocation of SOX9 during sexual determination. Proc Natl Acad Sci USA 2002; 99 : 11199–204.
  39. Malki S, Berta P, Poulat F, Boizet-Bonhoure B. Cytoplasmic retention of the sex-determining factor SOX9 via the microtubule network. Exp Cell Res 2005; 309 : 468–75.
  40. Kim Y, Kobayashi A, Sekido R, et al. Fgf9 and wnt4 act as antagonistic signals to regulate Mammalian sex determination. PLoS Biol 2006; 4 : e187.
  41. Pujol P, Rey JM, Nirde P, et al. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998; 58 : 5367–73.
  42. Munkarah AR, Morris R, Baumann P, et al. Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells. J Soc Gynecol Investig 2002; 9 : 168–73.
  43. Denkert C, Kobel M, Pest S, et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002; 160 : 893–903.
  44. Daikoku T, Wang D, Tranguch S, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 2005; 65 : 3735–44.
  45. Malki S, Bibeau F, Notarnicola C, et al. Expression and biological role of the prostaglandin D synthase/SOX9 pathway in human ovarian cancer cells. Cancer Lett 2007; 255 : 182–93
  46. Kikuchi Y, Kita T, Miyauchi M, et al. Inhibition of human ovarian cancer cell proliferation in vitro by neuroendocrine hormones. Gynecol Oncol 1989; 32 : 60–4.
  47. Kikuchi Y, Miyauchi M, Iwano I, et al. Adjuvant effects of prostaglandin D2 to cisplatin on human ovarian cancer cell growth in nude mice. Eur J Cancer Clin Oncol 1988; 24 : 1829–33.
  48. Su B, Guan M, Xia J, Lu Y. Stimulation of lipocalin-type prostaglandin D synthase by retinoic acid coincides with inhibition of cell proliferation in human 3AO ovarian cancer cells. Cell Biol Int 2003; 27 : 587–92.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.